In a move that could potentially signal greater flexibility by regulators in reviewing groundbreaking drugs with new mechanisms of action in rare diseases with clear unmet medical need, the FDA provided guidance for a potential regulatory path, under accelerated approval, for drisapersen, the lead program in development by Prosensa Holding NV to treat Duchenne muscular dystrophy (DMD).